Jazz Pharmaceuticals (JAZZ) Upgraded to “Hold” by BidaskClub

BidaskClub upgraded shares of Jazz Pharmaceuticals (NASDAQ:JAZZ) from a sell rating to a hold rating in a research report sent to investors on Friday morning.

Other equities analysts have also recently issued reports about the company. Seaport Global Securities set a $175.00 price objective on Jazz Pharmaceuticals and gave the stock a buy rating in a research note on Friday, April 6th. Wells Fargo restated a buy rating on shares of Jazz Pharmaceuticals in a research note on Monday, December 25th. B. Riley restated a buy rating and set a $206.00 price objective on shares of Jazz Pharmaceuticals in a research note on Wednesday, December 20th. Piper Jaffray restated a buy rating and set a $201.00 price objective on shares of Jazz Pharmaceuticals in a research note on Thursday, March 1st. Finally, Bank of America raised their price objective on Jazz Pharmaceuticals from $164.00 to $170.00 and gave the stock a buy rating in a research note on Tuesday, February 20th. Six research analysts have rated the stock with a hold rating and eighteen have issued a buy rating to the company’s stock. The company currently has a consensus rating of Buy and an average price target of $180.78.

How to Become a New Pot Stock Millionaire

Jazz Pharmaceuticals stock opened at $155.96 on Friday. The company has a market cap of $9,333.52, a PE ratio of 16.31, a price-to-earnings-growth ratio of 0.82 and a beta of 0.97. The company has a debt-to-equity ratio of 0.57, a current ratio of 3.29 and a quick ratio of 3.15. Jazz Pharmaceuticals has a 52 week low of $128.58 and a 52 week high of $163.75.

Jazz Pharmaceuticals (NASDAQ:JAZZ) last released its earnings results on Tuesday, February 27th. The specialty pharmaceutical company reported $2.58 EPS for the quarter, missing the Thomson Reuters’ consensus estimate of $2.73 by ($0.15). Jazz Pharmaceuticals had a net margin of 30.14% and a return on equity of 22.63%. The business had revenue of $436.40 million for the quarter, compared to analysts’ expectations of $440.91 million. analysts forecast that Jazz Pharmaceuticals will post 11.48 earnings per share for the current year.

In other news, EVP Michael Patrick Miller sold 200 shares of the firm’s stock in a transaction on Friday, April 13th. The stock was sold at an average price of $157.49, for a total transaction of $31,498.00. Following the transaction, the executive vice president now directly owns 27,481 shares of the company’s stock, valued at $4,327,982.69. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, SVP Karen J. Wilson sold 3,899 shares of the firm’s stock in a transaction on Tuesday, April 10th. The shares were sold at an average price of $155.00, for a total value of $604,345.00. Following the transaction, the senior vice president now directly owns 19,517 shares in the company, valued at $3,025,135. The disclosure for this sale can be found here. Insiders sold 13,957 shares of company stock worth $2,080,782 over the last quarter. 4.30% of the stock is currently owned by company insiders.

Institutional investors and hedge funds have recently modified their holdings of the company. HBK Investments L P increased its holdings in shares of Jazz Pharmaceuticals by 159.8% during the fourth quarter. HBK Investments L P now owns 22,600 shares of the specialty pharmaceutical company’s stock valued at $3,043,000 after purchasing an additional 13,900 shares during the period. Teachers Advisors LLC increased its holdings in shares of Jazz Pharmaceuticals by 16.1% during the fourth quarter. Teachers Advisors LLC now owns 601,785 shares of the specialty pharmaceutical company’s stock valued at $81,030,000 after purchasing an additional 83,426 shares during the period. Ellington Management Group LLC acquired a new position in shares of Jazz Pharmaceuticals during the fourth quarter valued at $633,000. Compagnie Lombard Odier SCmA acquired a new position in shares of Jazz Pharmaceuticals during the fourth quarter valued at $577,000. Finally, AXA increased its holdings in shares of Jazz Pharmaceuticals by 23.2% during the third quarter. AXA now owns 116,862 shares of the specialty pharmaceutical company’s stock valued at $17,091,000 after purchasing an additional 22,007 shares during the period. 91.21% of the stock is currently owned by institutional investors.

COPYRIGHT VIOLATION WARNING: “Jazz Pharmaceuticals (JAZZ) Upgraded to “Hold” by BidaskClub” was originally reported by Chaffey Breeze and is the sole property of of Chaffey Breeze. If you are accessing this piece on another publication, it was copied illegally and republished in violation of U.S. & international trademark & copyright legislation. The original version of this piece can be read at https://www.chaffeybreeze.com/2018/04/17/jazz-pharmaceuticals-jazz-upgraded-to-hold-by-bidaskclub.html.

About Jazz Pharmaceuticals

Jazz Pharmaceuticals plc, a biopharmaceutical company, identifies, develops, and commercializes pharmaceutical products for various medical needs in the United States, Europe, and internationally. The company has a portfolio of products and product candidates with a focus in the areas of sleep and hematology/oncology.

Analyst Recommendations for Jazz Pharmaceuticals (NASDAQ:JAZZ)

Receive News & Ratings for Jazz Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jazz Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply